Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition

Neurology

Volumn 67, Issue 7 SUPPL. 2, 2006, Pages

  Stocchi, F ^a   Vacca, L ^b   Grassini, P ^a   De Pandis, M F ^f   Battaglia, G ^b   Cattaneo, C ^c   Fariello, R G ^d,e  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c Newron Pharmaceuticals   (Italy)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e Newron Pharmaceuticals Spa   (Italy)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CABERGOLINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; LEVODOPA; PRAMIPEXOLE; ROPINIROLE; SAFINAMIDE;

ADULT; AGITATION; AREA UNDER THE CURVE; ARTICLE; AUDITORY HALLUCINATION; CLINICAL ARTICLE; CONFUSION; CYSTITIS; DOPAMINE RELEASE; DOPAMINE UPTAKE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; FEVER; GASTROINTESTINAL PAIN; HUMAN; INSOMNIA; LIBIDO DISORDER; MALE; MOTOR PERFORMANCE; NERVOUSNESS; NEUROTRANSMITTER RELEASE; PARKINSON DISEASE; PARKINSONISM; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL DISORDER; VISUAL HALLUCINATION;

EID: 33750000049     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.67.7_suppl_2.s24     Document Type: Article

References (19)

1. Fariello RG, McArthur, R, Bonsignori A, et al. Preclinical evaluation of PNU151774E as a novel anticonvulsant. J Pharmacol Exp Ther 1998;285:1151-1159.
2. Fariello RG, Caccia C. Safinamide. Effects on platelets MAO-B activity in healthy volunteers. Proc 5th International Conference on Progress in Alzheimer's and Parkinson's disease 2001. Abstract.
3. Mai R, Fariello R, Ukmar G, Varasi M, McArthur RA, Salvati P. PNU151774E protects against kainate-induced status epilepticus and hippocampal lesions in the rat. Eur J Pharmacol 1998;359:27-32.
4. Vaghi F, Maj R, Rosa B, et al. Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of Global Ischaemia in gerbils. Proc Society Neuroscience 1997. Abstract.
5. Caccia C, Maj R, Calabresi M, et al. Safinamide from molecular targets to a new antiparkinson drug, Neurology 2006;67(suppl 2):S18-S23.
6. Strolin Benedetti MS, Marrani P, Colombo M, et al. The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J Pharm Pharmacol 1994;46:814-819.
7. Cattaneo C, Caccia C, Marzo A, Maj R, Fariello RG. Pressure response to intravenous tyramine in healthy subjects after safinamide, a novel neuroprotectant with selective reversible monoamino oxidase B inhibition. Clin Neuropharmacol 2003;26:203-213.
8. Stocchi F, Arnold G, Kwiecinski H, et al. Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63:746-748.
9. Robinson DS, Lovenberg W, Keiser H, Sjordsma A. Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol 1968;17:109-119.
10. Blandini F, Martignoni E, Pacchetti C, et al. Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr [B] Biomed Sci Appl 1997;700:278-282.
11. Perucca E, Onofrj M, Thomas A, Cattaneo C, Fariello RG. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res 2004;61:12-14.
12. Ruottinen HM, Rinne UK. Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996;19:222-233.
13. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-919.
14. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36-40.
15. Napolitano A, Del Dotto P, Petrozzi L, et al. Pharmacokinetics and pharmacodynamics of L-DOPA after acute and 6-week tolcapone administration in patients with Parkinson's disease. Clin Neuropharmacol 1999;22:24-29.
16. Parkinson Study Group. A randomized controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 2001;56:455-463.
17. Zipp F, Burklin F, Stecker K, Baas H, Fischer PA. Lamotrigine in Parkinson's disease-a double blind study. J Neural Transm Park Dis Dement Sect 1995;10:199-206.
18. Jancovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002;8:271-276.
19. Shinotoh H, Vingerhoets FJ, Lee CS, et al. Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, cross-over study. Neurology 1997;48:1282-1285.